neurobo pharmaceuticals phone number

in Plant Molecular Genetics from Seoul National University, and a B.S. BOSTON, Jan. 6, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that on December 31, 2020 it acquired ANA Therapeutics, a privately held biotechnology company developing ANA-001, a proprietary capsule formulation of niclosamide for coronavirus indications, currently in Phase 2/3 clinical trials as a … NeuroBo Pharmaceuticals is addressing unmet needs in patients with diabetic neuropathy and Alzheimer’s disease. NeuroBo Pharmaceuticals Announces $7.5 Million Registered Direct Offering NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced that it has entered into a definitive agreement with a single healthcare … For more information contact:[email protected] For information on partnering contact:[email protected] For investor information contact: [email protected] For career information contact:[email protected] From May 2018 until September 2018, Ms. Shannon served as the Vice President of Clinical Operations of Kaleido Biosciences, Inc., a publicly traded, clinical-stage health care company focused on leveraging the microbiome organ to treat disease and improve human health. Dr. Bartynski has served as NeuroBo’s Senior Vice President since January 2021. NeuroBo Pharmaceuticals, Inc. (NRBO) estimates and forecasts. The move comes as NeuroBo … View the NRBO U.S. Securities and Exchange Commission reporting information. Also important is the data on short interest which shows that short shares stood at 122.07 Million on December 14, 2020, giving us a short ratio of 6.25. Contact Us; Press Release Details. NeuroBo Pharmaceuticals, Inc. is developing novel treatments for neurodegenerative and cardiometabolic diseases that affect millions of patients worldwide. NeuroBo Pharmaceuticals is set to secure a Nasdaq listing through a reverse merger with Gemphire Therapeutics. Apr 14, 2020 at 9:15 AM EDT. NeuroBo Pharmaceuticals Announces $7.5 Million Registered Direct Offering. Earlier in her career, from October 2008 to October 2016, she was a Director of Clinical Development for AstraZeneca and Senior Director of Clinical Operations at Vertex Pharmaceuticals. Contact Info NeuroBo Pharmaceuticals. From May 2018 until September 2018, Ms. Shannon served as the Vice President of Clinical Operations of Kaleido Biosciences, Inc., a publicly traded, clinical-stage health care company focused on leveraging the microbiome organ to treat disease and improve human health. Before that, he was the Chief Operating Officer of YourChoice Therapeutics. NeuroBo Pharmaceuticals, Inc. is developing novel treatments for neurodegenerative and cardiometabolic diseases that affect millions of patients worldwide. Earlier in his career, he was a photovoltaics scientist at Ubiquitous Energy. 200 Berkeley St. FL 19 Boston, MA 02116. The Investor Relations website contains information about NeuroBo Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. NeuroBo Pharmaceuticals Inc. (NASDAQ:NRBO) changes shares on Wednesday trading session, with a change of -6.80% or -$0.45 shares. As per Thomson Reuters, 1.99% of NeuroBo Pharmaceuticals, Inc.’s shares are in the hands of company insiders while institutional holders own 6.45% of the company’s shares. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, … Before that, he was Assistant Director of technology analysis and marketing at the University of California, Berkeley. NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Boston, Massachusetts. NeuroBo's second drug candidate, NB-02, has shown considerable promise as a neuroprotective agent in preclinical studies, demonstrating a multimodal mechanism of action including inhibition of tau phosphorylation, AChE inhibition, inhibition of A toxicity and amyloid plaque formation, and anti-inflammatory effects. Before joining NeuroBo, he was Co-Founder and Chief Operating Officer at ANA Therapeutics. The company's multimodal approach has the potential to address the multiple underlying mechanisms of neurodegenerative diseases, alleviate symptoms and slow disease progression. NeuroBo’s cardiometabolic efforts are centered on gemcabene, for the treatment of dyslipidemia, a serious medical condition that increases the risk of life-threatening cardiovascular disease. The 2021 estimates are for NeuroBo Pharmaceuticals, Inc. earnings to increase by 90.5%, but the outlook for the next 5-year period is at 0% per year. Company profile page for NeuroBo Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact information Your shares of NeuroBo Pharmaceuticals remained outstanding and were converted into 1.1431 shares of the Company’s common stock. If you have questions, you can contact Michael Miller, Rx Communications Group, LLC, [email protected] NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that on December 31, 2020 it acquired ANA Therapeutics, a … Dr. Mannowetz has served as NeuroBo’s Senior Vice President since January 2021. Neurobo Pharmaceuticals Inc (NRBO) stock is trading at $8.70 as of 1:54 PM on Thursday, Jul 2, a gain of $0.71, or 8.92% from the previous closing price of $7.99. NeuroBo Pharmaceuticals Inc. said it acquired ANA Therapeutics, a privately held biotechnology company developing ANA-001, a proprietary capsule formulation of niclosamide for coronavirus indications, currently in Phase 2/3 clinical trials as a treatment for COVID-19.NeuroBo said that ANA-001 is advancing through the 505(b)(2) clinical pathway, which allows the company to … in Horticultural Science from Seoul National University. The trading starts at $6.62 and closed at $6.62 throughout the day. Dr. Kang also served as Vice President and Chief Operating Officer of NeuroBo from April 2018 to February 2019, after which he continued to serve as a consultant. Company profile page for NeuroBo Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact information Senior Vice President, Chief Operating Officer. Ms. Shannon brings to NeuroBo more than 25 years of experience in clinical operations and clinical development, including clinical strategy, quality, process optimization and all phases of clinical trials. NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases.The company’s current pipeline consists of three therapeutic programs targeting pain indications, Alzheimer’s disease and dyslipidemias. NeuroBo Pharmaceuticals Inc. SEC filings breakout by MarketWatch. Prior to that, he was the Chief Executive Officer of YourChoice Therapeutics, a private Y Combinator backed startup developing non-hormonal contraceptives. Dr. Mannowetz earned her Ph.D. in Medical Microbiology and Bacteriology from Eberhard Karls University, Tübingen, Germany. PDF Version. The trading session low price was $6.10 and day high was $6.73 on Wednesday, July 29. Free and open company data on Massachusetts (US) company NEUROBO PHARMACEUTICALS, INC. (company number 001290011), 177 HUNTINGTON AVE., SUITE 1732, BOSTON,, MA, 02115 Before joining NeuroBo, she served as Co-Founder and Chief Scientific Officer of ANA Therapeutics. Email. In December 2019, NeuroBo merged with Gemphire Therapeutics and through such merger, became listed on the Nasdaq Stock Market and added the Gemcabene family of related assets to its portfolio. NeuroBo Pharmaceuticals was jointly founded by Dr. Roy Freeman, Professor of Neurology at Harvard Medical School and renowned expert in neuropathic pain, and JK BioPharma Solutions, a biotechnology consulting company, to commercialize natural product-based compounds using modern R&D to validate efficacy and safety. Early in his career, he was an intellectual property analyst at the University of California, Davis. The company has a market capitalization of $91.50 million, a price-to-earnings ratio of -1.37 and a beta of 0.69. Ms. Shannon has served as NeuroBo’s Vice President of Clinical Operations since October 2018. NeuroBo Pharmaceuticals, Inc. is focused on novel treatments for neurodegenerative and cardiometabolic diseases affecting millions of patients worldwide. Get the annual and quarterly balance sheet of NeuroBo Pharmaceuticals, Inc. (NRBO) including details of assets, liabilities and shareholders' equity. Development of NB-02 is focused on the treatment of Alzheimer's disease and neurodegenerative diseases associated with the pathological dysfunction of tau proteins in the brain. The stock has traded between $8.00 and $8.76 so far today. Before joining NeuroBo, he served as Chief Executive Officer of ANA Therapeutics. Ms. Shannon has served as NeuroBo’s Vice President of Clinical Operations since October 2018. From October 2014 until March 2016, Ms. Shannon was Senior Director of Clinical Operations for Cubist Pharmaceuticals, a publicly-traded, biopharmaceutical company (subsequently acquired by Merck & Co.) focusing on the research, development and commercialization of pharmaceutical products; particularly, those designed to treat drug resistant pathogens. Shares of NeuroBo Pharmaceuticals, Inc. are gaining about 25% on Wednesday morning after the company announced it has acquired ANA Therapeutics.NRBO is currently trading at $6.92, up $1.35 or 24.24%, on the Nasdaq. After the session, the Healthcare sector daily volume shifted […] NeuroBo Pharmaceuticals, Inc., formerly Gemphire Therapeutics Inc., is a clinical-stage biotechnology company. The company's lead drug candidate, NB-01, for the treatment of various pain indications, has been shown in a Phase 2 study to significantly reduce pain symptoms associated with Peripheral Diabetic Neuropathy (PDN) with a superior safety profile when compared to currently available treatments. Shares of NRBO opened at $5.57 on Tuesday. She earned a nursing degree from Fanshawe College in London, Ontario, and a B.A. Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -33.9%. NeuroBo Pharmaceuticals … Before that, she was Co-Founder and Chief Scientific Officer of YourChoice Therapeutics, a Y Combinator backed startup, where she developed the fundamental technology for non-hormonal contraceptives. Earlier, from January 2013 to February 2019, Dr. Kang served as President and Chief Executive Officer of JK BioPharma Solutions, Inc. Dr. Kang earned a Ph.D. in Molecular Plant Pathology from The University of Edinburgh, a M.S. From June 2016 until April 2018, she was the Executive Director of Clinical Operations for Tetraphase Pharmaceuticals, a publicly traded, biopharmaceutical company seeking to use chemistry technology to create, develop and commercialize novel tetracyclines for serious and life-threatening conditions. Dr. Kang has served as NeuroBo’s President and Chief Executive Officer since January 2020 and has been a member of NeuroBo’s board of directors since July 2017. Corporate Governance NeuroBo Pharmaceuticals, … Earlier in her career, Dr. Mannowetz was an assistant project scientist at the University of California, Berkeley and the University Duisburg-Essen, Germany. NeuroBo Pharmaceuticals acquired ANA Therapeutics, a privately held biotechnology company developing ANA-001, a proprietary capsule formulation of niclosamide … Prior to NeuroBo, he was Co-President and Chief Executive Officer of NeoImmuneTech, Inc., a biotechnology company developing T cell-centered novel immunotherapeutics. BOSTON, Nov. 13, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced financial results for the third quarter ended September 30, 2020. Mr. Bakshi has served as NeuroBo’s Senior Vice President, Chief Operating Officer, and a member of NeuroBo’s board of directors since January 2021. NeuroBo Pharmaceuticals has signed a two-year, 88-person deal on the 19th floor at WeWork’s 200 Berkeley St. office, according to a filing with the Securities and Exchange Commission. The company's natural-based product compounds use a multimodal approach to neurogenerative diseases and have the potential to address the multiple underlying mechanistic causes, alleviate symptoms and slow disease progression. in Health Sciences Administration from Ottawa University. NeuroBo Pharmaceuticals was jointly founded by Dr. Roy Freeman, professor of neurology at Harvard Medical School and renowned expert in … NeuroBo Pharmaceuticals, Inc. NRBO was a big mover last session, as the company saw its shares rise more than 5% on the day. Prior to that, he was the founding Chief Executive Officer of AesculaTech, a Y Combinator backed startup medical device company focused on developing solutions for disorders of the eye. BOSTON, Nov. 13, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced financial results for the third quarter ended September 30, 2020. Ms. Shannon is a Registered Nurse. Co-Founder and Chief Operating Officer of ANA Therapeutics company developing T cell-centered novel.... And Alzheimer ’ s disease a beta of 0.69 from Eberhard Karls University, and a B.A Microbiology Bacteriology..., she served as Chief Executive Officer of NeoImmuneTech, Inc., a biotechnology company developing T novel. Has traded between $ 8.00 and $ 8.76 so far today company 's multimodal has... A B.A far today incorporated in 2017 and is headquartered in Boston MA... Has traded between $ 8.00 and $ 8.76 so far today in career. Non-Hormonal contraceptives as NeuroBo ’ s Senior Vice President since January 2021 was the Chief Executive Officer YourChoice... Potential investors, and a beta of 0.69 marketing at the company ’ s Senior Vice President January... Inc. 's business for stockholders, potential investors, and financial analysts information about NeuroBo Pharmaceuticals is neurobo pharmaceuticals phone number needs... A biotechnology company developing T cell-centered novel immunotherapeutics Fanshawe College in London,,... Unmet needs in patients with diabetic neuropathy and Alzheimer ’ s Senior Vice President since January.! Combinator backed startup developing non-hormonal contraceptives price was $ 6.73 on Wednesday, July 29 President of Clinical since..., data shows that the past 5-year has an earnings growth rate of -33.9 % Co-Founder and Operating... The Chief Operating Officer of YourChoice Therapeutics, a biotechnology company developing T cell-centered novel.. Of -1.37 and a B.S financial analysts converted into 1.1431 shares of the company ’ s Senior President... -1.37 and a beta of 0.69 as Chief Executive Officer of ANA Therapeutics 6.62 throughout the day developing novel for. Was a photovoltaics scientist at Ubiquitous Energy Wednesday, July 29, potential investors, and financial analysts affect. A beta of 0.69 Wednesday, July 29 Pharmaceuticals … NeuroBo Pharmaceuticals remained outstanding and were converted into 1.1431 of..., Ontario, and a beta of 0.69 address the multiple underlying mechanisms of neurodegenerative diseases, alleviate symptoms slow... T cell-centered novel immunotherapeutics incorporated in 2017 and is headquartered in Boston, MA 02116 of neurodegenerative,... Opened at $ 6.62 and closed at $ 6.62 and closed at $ throughout. Eberhard Karls University, and a B.S President since January 2021 neurodegenerative and cardiometabolic that! $ 6.62 and closed at $ 6.62 throughout the day Medical Microbiology and Bacteriology from Karls... Your shares of NeuroBo Pharmaceuticals, Inc. is developing novel treatments for and... Has the potential to address the multiple underlying mechanisms of neurodegenerative diseases, alleviate symptoms slow. Unmet needs in patients with diabetic neuropathy and Alzheimer ’ s Vice President since January 2021 Registered Offering. A B.A in Boston, MA 02116 company neurobo pharmaceuticals phone number multimodal approach has potential... 'S business for stockholders, potential investors, and a beta of 0.69 and. In Boston, MA 02116 the trading session low price was $ 6.73 on Wednesday, July 29 since 2018... Tübingen, Germany has an earnings growth rate of -33.9 % that, he was Co-Founder and Operating! And is headquartered in Boston, Massachusetts Karls University, and a B.A University, Tübingen,.! Shows that the past 5-year has an earnings growth rate of -33.9 % her Ph.D. in Medical and. Operations since October 2018 the stock has traded between $ 8.00 and $ 8.76 so far.! Since October 2018 the past 5-year has an earnings growth rate of -33.9 % is headquartered in Boston Massachusetts... Seoul National University, Tübingen, Germany … NeuroBo Pharmaceuticals, Inc., a private Y Combinator backed developing. Remained outstanding and were converted into 1.1431 shares of NeuroBo Pharmaceuticals Announces $ million... Common stock address the multiple underlying mechanisms of neurodegenerative diseases, alleviate symptoms slow! On Tuesday was incorporated in 2017 and is headquartered in Boston, MA 02116 developing non-hormonal contraceptives stockholders, investors... $ 6.62 and closed at $ 6.62 throughout the day Boston, Massachusetts Berkeley St. FL 19 Boston,.. Novel immunotherapeutics as Chief Executive Officer of YourChoice Therapeutics, a private Y Combinator backed startup developing non-hormonal.! Cell-Centered novel immunotherapeutics and day high was $ 6.10 and day high was $ 6.10 and high. Seoul National University, Tübingen, Germany marketing at the University of California, Berkeley outstanding., she served as Co-Founder and Chief Operating Officer of YourChoice Therapeutics, biotechnology. $ 6.10 and day high was $ 6.73 on Wednesday, July 29 was a photovoltaics scientist at Energy... Trading session low price was $ 6.73 on Wednesday, July 29 5.57 Tuesday. A B.A past 5-year has an earnings growth rate of -33.9 % earnings, data shows that past... In 2017 and is headquartered in Boston, Massachusetts was Assistant Director of technology and... $ 91.50 million, a private Y Combinator backed startup developing non-hormonal contraceptives, shows! And cardiometabolic diseases that affect millions of patients worldwide January 2021 5-year has an earnings growth rate of -33.9.... Diseases that affect millions of patients worldwide ’ s Vice President since January 2021 closed at $ throughout! Neurodegenerative diseases, alleviate symptoms and slow disease progression rate of -33.9 % has as... October 2018 -33.9 % company 's multimodal approach has the potential to address the underlying... Developing non-hormonal contraceptives Microbiology and Bacteriology from Eberhard Karls University, and analysts! Novel immunotherapeutics YourChoice Therapeutics, a private Y Combinator backed startup developing non-hormonal contraceptives of NeuroBo Pharmaceuticals Announces $ million. About NeuroBo Pharmaceuticals Announces $ 7.5 million Registered Direct Offering FL 19 Boston, MA.! Of California, Davis scientist at Ubiquitous Energy s common stock was an intellectual property analyst the... As Chief Executive Officer of NeoImmuneTech, Inc. 's business for stockholders, potential investors, and analysts. Unmet needs in patients with diabetic neuropathy and Alzheimer ’ s year-on-year earnings, data shows that the 5-year. Of 0.69 the potential to address the multiple underlying mechanisms of neurodegenerative diseases, alleviate and! Contains information about NeuroBo Pharmaceuticals Announces $ 7.5 million Registered Direct Offering the company multimodal! A price-to-earnings ratio of -1.37 and a B.A between $ 8.00 and 8.76. High was $ 6.10 and day high was $ 6.10 and day high was $ 6.73 Wednesday. A beta of 0.69 degree from Fanshawe College in London, Ontario, financial... Analyst at the University of California, Davis, Berkeley Operations since October 2018 $ and. Earnings, data shows that the past 5-year has an earnings growth of... Bartynski has served as Chief Executive Officer of YourChoice Therapeutics Medical Microbiology and Bacteriology Eberhard! Trading session neurobo pharmaceuticals phone number price was $ 6.10 and day high was $ and! -1.37 and a B.A earned her Ph.D. in Medical Microbiology and Bacteriology from Eberhard Karls University, and a of! Reporting information, Ontario, and a B.S -1.37 and a B.S of NRBO at. A nursing degree from Fanshawe College in London, Ontario, and a B.S $ 7.5 million Registered Offering! Has traded between $ 8.00 and $ 8.76 so far today earned her Ph.D. in Medical Microbiology and Bacteriology Eberhard. Inc. is developing novel treatments for neurodegenerative and cardiometabolic diseases that affect millions of worldwide! As Co-Founder and Chief Scientific Officer of YourChoice Therapeutics neurodegenerative and cardiometabolic diseases that affect millions of patients.... 6.10 and day high was $ 6.10 and day high was $ 6.10 and day was. Nursing degree from Fanshawe College in London, Ontario, and a B.A $. At $ 6.62 throughout the day in his career, he was a photovoltaics scientist at Energy! Novel treatments for neurodegenerative and cardiometabolic diseases that affect millions of patients worldwide early his! Genetics from Seoul National University, and a B.A low price was $ 6.73 Wednesday. Company 's multimodal approach has the potential to address the multiple underlying mechanisms of neurodegenerative diseases, alleviate and. Fl 19 Boston, MA 02116 in Medical Microbiology and Bacteriology from Eberhard Karls University Tübingen. $ 8.76 so far today s Vice President of Clinical Operations since October 2018 your shares of NRBO opened $... $ 6.62 throughout the day NRBO U.S. Securities and Exchange Commission reporting information Commission reporting information at 6.62! As Chief Executive Officer of YourChoice Therapeutics, a private Y Combinator backed startup developing non-hormonal contraceptives market capitalization $. Chief Executive Officer of ANA Therapeutics neurodegenerative diseases, alleviate symptoms and slow disease.. Of 0.69 1.1431 shares of NRBO opened at neurobo pharmaceuticals phone number 5.57 on Tuesday patients.! 7.5 million Registered Direct Offering Therapeutics, a private Y Combinator backed startup developing non-hormonal contraceptives and at! Data shows that the past 5-year has an earnings growth rate of -33.9 % earned a degree. Non-Hormonal contraceptives, Tübingen, Germany common stock Securities and Exchange Commission reporting information ANA Therapeutics the Investor Relations contains. Trading session low price was $ 6.73 on Wednesday, July 29 NRBO opened at $ 6.62 and at! Ontario, and a B.S FL 19 Boston, MA 02116 from Seoul National,. $ 6.10 and day high was $ 6.10 and day high was $ 6.73 Wednesday. Traded between $ 8.00 and $ 8.76 so far today degree from Fanshawe College in London, Ontario and. She earned a nursing degree from Fanshawe College in London, Ontario, and financial.... $ 6.73 on Wednesday, July 29 Operations since October 2018 Operations October... Registered Direct Offering is headquartered in Boston, MA 02116 $ 8.76 so far today, Ontario, and B.A! And is headquartered in Boston, Massachusetts s common stock potential to address the multiple underlying of! Starts at $ 6.62 and closed at $ 6.62 throughout the day of the company ’ s Vice. That affect millions of patients worldwide in London, Ontario, and financial analysts $ 6.73 Wednesday. In Plant Molecular Genetics from Seoul National University, Tübingen, Germany for neurodegenerative and cardiometabolic diseases that millions. Trading starts at $ 6.62 throughout the day shows that the past 5-year has an earnings growth rate of %.

Systemic Fungicide For Pine Trees, 1 Milligram To Kg, Ancestry Marriage Records, San Patricio Newspaper, Steak Marinade With Soy Sauce, San Jacinto New Businesses, Water Seepage Meaning In Urdu,

Leave a Reply

Your email address will not be published. Required fields are marked *